<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00106314</url>
  </required_header>
  <id_info>
    <org_study_id>CL-C002-00</org_study_id>
    <nct_id>NCT00106314</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inflabloc Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inflabloc Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Inflabloc Cap
      (Dehydroepiandrosterone [DHEA]) in the treatment of patients with moderately active Crohn's
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, multi-center, dose response, efficacy and safety study of
      Inflabloc Cap in patients with moderately active Crohn's disease. The primary objectives of
      the study are to evaluate the efficacy and safety of Inflabloc Cap in the treatment of
      patients with moderately active Crohn's disease who also have elevated CRP.

      The study will be conducted at approximately 20 centers. Each patient will undergo screening
      followed by 8 weeks of treatment with Inflabloc Cap. Eligible male and female patients will
      be randomized in a 1:1:1 ratio to placebo, 30 mg, or 60 mg of DHEA administered twice daily
      via Inflabloc Cap so that approximately 60 patients complete the study. Following the
      Screening evaluations, consenting patients will self-administer 2 doses/day of study
      medication (placebo, 30 mg, or 60 mg of DHEA via Inflabloc Cap) for a total of 8 weeks
      (approximately 56 days). Patients will be required to complete a daily diary containing
      evaluations for number of liquid and soft stools, abdominal pain, fever and general
      well-being. Patients will also record use of study drug, concomitant medications and adverse
      events on the daily diary. Patients will be required to visit the study center at Screening,
      Baseline and at Weeks 1, 2, 4 and 8 following the initiation of treatment to turn in their
      diaries and any unused study medication, receive a physical exam and submit blood samples for
      chemistry, hematology and specialty laboratory measurements, and a urine sample for
      urinalysis. A stool sample is also required at Screening for culture and assay for C.
      difficile toxin. In addition, at the 8-week visit, patients will receive an exit exam
      including a physical exam (with ECG and vitals) and submit blood samples for chemistry,
      hematology and specialty laboratory measurements and a urine sample for urinalysis.

      The primary efficacy endpoint for this study is defined as achieving a CDAI of 150 or less
      after 8 weeks of treatment. Secondary and exploratory efficacy endpoints at Weeks 4 and 8
      will include achieving a CDAI of 150 or less (at 4 weeks), a change in CDAI from baseline of
      at least 100 points, a change from baseline in CRP, change from baseline in diarrhea and
      abdominal pain sub-scores, and change from baseline in IBDQ. Additionally, the safety of
      Inflabloc Cap when administered to patients with moderately active Crohn's disease with
      elevated CRP will be monitored through clinical evaluation, clinical laboratory data,
      collection of Adverse Events and other relevant safety evaluations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieving CDAI (Crohn's Disease Activity Index) of 150 or less after 8 weeks of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieving a CDAI score of 150 or less at 4 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CDAI from baseline of at least 100 points at 4 and 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP (C-Reactive Protein) from baseline at 4 and 8 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life from baseline at 8 weeks as measured by the Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diarrhea and abdominal pain sub-scores from CDAI</measure>
  </secondary_outcome>
  <enrollment>75</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dehydroepiandrosterone [DHEA]</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Crohn's disease made at least 3 months prior to study entry.

          -  C-reactive protein above the upper limit of normal.

          -  Currently have moderately active Crohn's disease.

        Exclusion Criteria:

          -  Women who are pregnant or lactating or of childbearing potential.

          -  History of colostomy, ileostomy, intestinal resection resulting in short bowel
             syndrome or symptomatic strictures.

          -  Symptoms (abdominal pain, vomiting) and radiographic evidence of mechanical bowel
             obstruction within the previous 6 months.

          -  Fistulizing disease.

          -  Positive stool culture for enteric pathogens and/or C. difficile toxin.

          -  History of significant disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul A. Litka, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inflabloc Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Associates</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Rees-Stealy Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Gastroenterologists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Department of Internal Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Clinical Trials</name>
      <address>
        <city>Severna Park</city>
        <state>Maryland</state>
        <zip>21146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jason Bodzin, MD</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>43884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Center for Clinical Research</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Gastroenterology and Hepatology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation, Dept. of Gastroenterology</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Center for Digestive Health</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atilla Ertan, MD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountain West Gastroenterology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG Reseach</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine / Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC GI (111N)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center, Department of Gastroenterology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tacoma Digestive Disease Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wisconsin Center for Advanced Research</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GILDR Group</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan Cockeram, MD</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2K 1J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBD Clinical and Research Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>New Brunswick</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doug Hemphill, MD</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 5G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Digestive Disease Group</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philip Hassard, MD</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1K 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Medical Specialists</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Andus T, Klebl F, Rogler G, Bregenzer N, Sch√∂lmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther. 2003 Feb;17(3):409-14.</citation>
    <PMID>12562454</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2005</study_first_submitted>
  <study_first_submitted_qc>March 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2005</study_first_posted>
  <last_update_submitted>October 17, 2007</last_update_submitted>
  <last_update_submitted_qc>October 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <keyword>Dehydroepiandrosterone</keyword>
  <keyword>DHEA</keyword>
  <keyword>Crohn's disease</keyword>
  <keyword>C-reactive protein</keyword>
  <keyword>CRP</keyword>
  <keyword>Crohn's Disease Activity Index</keyword>
  <keyword>CDAI</keyword>
  <keyword>Inflammatory Bowel Disease Questionnaire</keyword>
  <keyword>IBDQ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

